Zhongsheng Pharmaceutical announced that the company held the 5th meeting of the 9th board of directors on August 17, 2026 to review and pass the relevant bill, agreeing to use its own capital of US$28.2621 million to acquire 12.06% of its total holding subsidiary Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd. from Southern Orchard Limited, Snow Owl LLC, BioTrack Capital Fund I, LP. After the acquisition is completed, the company's shareholding ratio in Zhongsheng Ruichuang will increase from 77.12% to 89.18%, and Zhongsheng Ruichuang is still the company's holding subsidiary.

Zhongsheng Pharmaceutical announced that the company held the 5th meeting of the 9th board of directors on August 17, 2026 to review and pass the relevant bill, agreeing to use its own capital of US$28.2621 million to acquire 12.06% of its total holding subsidiary Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd. from Southern Orchard Limited, Snow Owl LLC, BioTrack Capital Fund I, LP. After the acquisition is completed, the company's shareholding ratio in Zhongsheng Ruichuang will increase from 77.12% to 89.18%, and Zhongsheng Ruichuang is still the company's holding subsidiary.